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Abstract
Microarrays are a powerful tool that have multiple applications both in clinical and cell biology
arenas of common lung diseases. To exemplify how this tool can be useful, in this review, we will
provide an overview of the application of microarray technology in research relevant to common
lung diseases and present some of the future perspectives.
Introduction
Microarray technology is rapidly becoming a standard
technology used in research laboratories all across the
world. Since its first application in the mid 1990s [1]
microarray technology has been successfully applied to
almost every aspect of biomedical research [2-7] with over
250 papers in respiratory research alone. Research con-
ducted the last ten years has elevated the status of micro-
array technology from poorly understood and doubtfully
applied in the fields of medicine to one that requires
attention when the examination of clusters of genes in a
single experiment is considered. Far more progress has
been made toward an understanding of the pivotal role of
microarrays in respiratory research by providing the scien-
tists well-established knowledge concerning numerous
genes that can be used as potential drug targets, mediators
and inflammatory molecules with important cellular
functions, evidence that captured the interest of both cli-
nicians and researchers and caused a consecutive year by
year rise of the applications of microarrays in experiments
designed to study pulmonary diseases. Thus microarray
technology since its first application [8] in the field of res-
piratory medicine has already been used the past five years
in almost every aspect of respiratory research with an
increased rate of application resulting to an overall of
approximately 250 published papers until now (Figures 1,
2). Though the majority of experiments using microarray
platforms was designed to study lung cancer (Figure 2) we
excluded from this review this data, because considering
the number of published papers, the enormous data
derived from these experiments could compile a separate
review article on its own. The scope of this review was
based on the fact that although there are numerous origi-
nal published papers using this pioneering method, the
number of review articles summarizing the importance of
microarrays in the research field relevant with pulmonary
diseases still remains inadequately small.
Applications of microarrays in medicine
DNA microarrays, microscopic arrays of large sets of DNA
sequences immobilized on solid substrates, are valuable
tools in areas of research that require the identification or
quantitation of many specific DNA sequences in complex
nucleic acid samples [8]. They are ordered samples of
DNA and each sample represents a particular gene. These
arrays can then be assayed for changes in the expression
patterns of the representative genes after different treat-
ments, different conditions or tissue sources. There are
Published: 07 December 2004
Respiratory Research 2004, 5:26 doi:10.1186/1465-9921-5-26
Received: 26 September 2004
Accepted: 07 December 2004
This article is available from: http://respiratory-research.com/content/5/1/26
© 2004 Tzouvelekis et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
Page 2 of 18
(page number not for citation purposes)
numerous ways to measure gene expression including
northern blotting, differential display, serial analysis of
gene expression and dot-blot analysis. The problem with
all these techniques is that they are unsuitable for the par-
allel testing of multiple genes' expression. Microarrays,
based on Southern's method of nucleotide hybridization,
contain multiple DNA sequences (probes) spotted or syn-
thetized on a relatively small surface. This feature of
microarrays allows the simultaneous monitoring of the
expression of thousands of genes, thus providing a func-
tional aspect to sequence information, in a given sample
[9]. Currently, genomic microarrays are used in medicine
for the following purposes: [10-13]
1. Determination of transcriptional programs of cells for a
given cellular function (e.g., cell function, cell differentia-
tion, etc.) or when they are exposed to certain conditions
leading to activation, inhibition or apoptosis.
2. Compare and contrast transcriptional programs to aid
diagnosis of diseases, predict therapeutic response and
provide class discovery and sub-classification of diseases.
3. Identification of genome-wide binding sites for tran-
scriptional factors that regulate the transcription of genes.
4. Prediction of gene function.
5. Identification of new therapeutic targets (target identi-
fication, target validation, and drug toxicity).
6. Development of public databases that will help us
understand the functioning of complex biological
systems.
7. Genetics of gene expression: Although this is a relatively
new study field, it is advancing rapidly with major impli-
cations in complex clinical traits by the identification of
promising candidate genes. Thus, we briefly review the
current implementations of this novel approach high-
lighting its necessity in the research field. Treating mRNA
transcript abundances as quantitative traits and mapping
gene expression quantitative trait loci for these traits has
been pursued in gene-specific ways. Unlike classical quan-
titative traits, the genetic linkages associated with
transcript abundance permits a more precise look at cellu-
lar biochemical processes. Schadt et al. [14] described
comprehensive genetic screens of three specific transcrip-
tomes by considering gene expression values as quantita-
tive traits. Authors treated the gene expression levels
derived by a microarray analysis in mice liver tissues as
quantitative traits in a standard linkage analysis using
evenly spaced autosomal markers. Interestingly they
found that a substantial portion of these genes had at least
one significant gene expression quantitative trait locus
(eQTL) depending on the LOD (log odds ratios) scores.
Since transcript abundances are increasingly used as surro-
gates for clinical traits, knowledge about their genetic con-
trol can help dissect the genetics of complex traits. In the
same study investigators revealed the importance of LOD
scores to differentiate whether the expression levels of the
genes under study is regulated by variations within the
gene itself (cis) or at a separate locus (trans). They found
that eQTL with LOD scores are cis acting (gene affects
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transcription of the gene itself) in most cases, whereas
moderately significant eQTL are trans acting (genes acting
on the transcription of other genes). Furthermore this
study undertook an investigation on how the heritability
of gene expression can be studied within and between
families and demonstrated that a significant portion of
differentially expressed genes derived from reference fam-
ilies had a detectable genetic component. The latter find-
ing suggests that this group of genes may serve as novel
therapeutic targets for complex human diseases, given
that their degree of genetic control was so readily identifi-
able in a small number of families.
Microarray technologies
DNA microarrays are used to estimate the levels of mRNA
in the cell. The process can be described in three steps:
1) Array construction: Currently, there are two widely used
microarray technologies:
• In situ synthetized oligonucleotide (20–25 mers) micro-
arrays-mainly oligonucleotides synthetized by photoli-
thography or ink-jet technology on a glass surface.
• Spotted, in glass or nylon membrane matrices, microar-
rays-mostly created by robotic printing of pre-prepared
cDNAs or oligonucleotides (polymerase chain reaction-
PCR-generated products from cDNA libraries or clone col-
lections) [9,15].
2) Sample preparation and array hybridization: The next step
in the microarray experiment is to prepare the material
that will be hybridized with the microarray. Gene expres-
sion is measured by the amount of mRNA therefore it
must be extracted from the sample cells or tissues. For
high-density microarrays one has to convert mRNA into
cRNA, whereas for spotted arrays one can use mRNA,
cDNA, or cRNA. The RNA needs to be labeled so that the
detecting machinery can measure the quantity of RNA
present. In oligonucleotide microarrays mRNA is
extracted from experimental samples and is labeled with a
fluorescent oligonucleotide (biotin). The biotin labeled
cRNA and each sample is hybridized to a separate array,
the array is scanned and absolute expression levels are
obtained for each probe by using a dedicated laser scan-
ner. In contrast, in spotted microarrays, mRNA is extracted
from a sample and a control and one is labeled with cy-5
(red fluorescent dye) and the other with cy-3 (green fluo-
rescent dye). Expression values are based on the
competitive hybridization of the two samples being
directly compared on a single array. Conventionally, in
radioactive nylon membrane arrays RNA probes are
labeled with P33 or P32 dCTP during a reverse transcription
reaction. The great advantage of nylon microarrays is that
they require relatively small amounts of PCR products
because radioactive targets have a higher intrinsic detecta-
bility whereas in glass arrays the quality of RNA is not as
critical as it is in nylon arrays. Therefore nylon arrays are
mainly used when sample material is scarce or a small
number of genes need to be assayed [16,17].
3) Image analysis and data acquisition: The laser causes exci-
tation of fluorescently or radioactively labeled cDNA
probes. Only the spots representing mRNAs in the sample
give emission signals. The emission is measured using a
scanning confocal laser microscope for fluorescently
labeled arrays or a flat-bed scanner for radioactive nylon
arrays and finally data is analyzed by appropriate soft-
ware. In spotted microarrays using fluorescent probes if
particular mRNA from the sample is in abundance, the
spot with a complementary probe will be red; if the con-
centration of the particular mRNA is higher in the control,
the spot will be green. If both samples contain the same
amount of a given mRNA, the spot will be yellow (Figure
3). In nylon membrane microarrays using radioactive
probes acquisition of phosphor-representations of radio-
active hybridizations is performed with a high resolution
digital autoradiography system displaying in real time the
quantitative image of radioisotopes deposited on biologi-
cal samples [18]. In high density oligonucleotide microar-
rays the absence of the fluorescence of the specific spots
means that complementary mRNA is not present in the
sample. If the fluorescence is present, the intensity of the
signal is a measure of the level of particular mRNAs in the
examined cell population [11-19].
Application of microarrays in pulmonary diseases
1. Microarrays in idiopathic pulmonary fibrosis (Table 1)
Idiopathic pulmonary fibrosis (IPF) is a refractory and
lethal interstitial lung disease characterized by fibroblast
proliferation, extracellular matrix (ECM) deposition and
progressive lung scarring. The incidence of IPF is esti-
mated at 15–40 cases per 100.000 per year, and the mean
survival from the time of diagnosis is 3–5 yr regardless of
treatment [20,21]. The etiology of IPF has remained elu-
sive and the molecular mechanisms are poorly under-
stood. To elucidate the molecular mechanisms that lead
to end-stage human pulmonary fibrosis Zuo et al. [22]
analyzed lung biopsy samples from five patients with clin-
ically, radiologically and histologically proven pulmonary
fibrosis (usual interstitial pneumonia-UIP) and compared
to samples from three resected lungs with normal histo-
logic findings, by using oligonucleotide microarrays.
Using a combined set of scoring systems they determined
that matrilysin (matrix metalloproteinase-MMP-7), a met-
alloprotease not previously associated with pulmonary
fibrosis, was the most informative increased gene in their
data set. Immunochemistry demonstrated increased
expression of matrilysin protein in fibrotic lungs derived
from different patients. Furthermore, in a separate set ofRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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experiments matrilysin knockout mice were dramatically
protected from pulmonary fibrosis in response to intratra-
cheal bleomycin. Their results identify matrilysin as a
mediator of pulmonary fibrosis and a potential therapeu-
tic target. Nevertheless potential limitations of the study
include the small sample size and the relative inability of
microarray analysis using whole lung homogenates to
assess the exact cells that were overexpressing the inform-
ative genes. The application of analytic microarray
approaches using gene expression signatures of specific
cell types coupled with advanced data mining computa-
tional tools will ameliorate this hardship.
In another study Kaminski et al. [23] used oligonucleotide
microarrays to analyze the gene expression programs that
underlie pulmonary fibrosis in response to bleomycin, in
two strains of susceptible mice. Microarray analysis per-
formed by different investigators and at different time
points demonstrated a considerable overlap between
genes induced by bleomycin in these two distinct strains
of mice. Differential gene expression in response to bleo-
mycin included upregulation of genes known to be asso-
ciated with bleomycin-induced lung injury and fibrosis
such as transforming growth factor-β1 (TGF-β1), as well
as genes not previously associated with the disease. Con-
firmational studies performed and further verified a por-
tion of the microarray data. Surprising insights were
derived from comparing gene expression patterns in
response to bleomycin of mice homozygous for a null
mutation of the integrin β6 subunit gene (β6 -/-), thus pro-
tected from pulmonary fibrosis, and wild type mice. Inter-
estingly a simple hierarchical cluster analysis identified
most of the known TGF-β1 inducible genes preferentially
induced in wild type mice. The latter finding provides sup-
port for the hypothesis that β6 knockout mice are pro-
tected from pulmonary fibrosis as a consequence of
failure to activate TGF-β. The great importance of this
study results from the identification and the global avail-
ability of several genes that are likely to be directly rele-
vant to the fibrotic process. However the inability of
microarray technology to detect genes that are not
included in the array, identify critical proteins that partic-
ipate in biological responses and ascribe changes in gene
expression in specific cellular types limit the scientific
rigidity of the data derived and highlights the necessity for
combined application of novel approaches.
Furthermore driven by the same perspective idea to inves-
tigate the gene expression pattern in bleomycin-induced
pulmonary fibrosis, Katsuma et al. [24] constructed a lung
chip derived from a normalized lung cDNA. They per-
formed large-scale analyses of gene expression and illumi-
nated a time-dependent change in the expression profile
of genes related to the inflammatory and fibrotic
responses in this model of pulmonary fibrosis, similar to
that observed by Kaminski et al [18]. Using cluster analy-
sis they classified genes into groups based on a time-
dependent gene expression. Interestingly this profile was
well correlated with observed histopathological changes
and data was confirmed with real time-(RT)-PCR
Image from laser scanning confocal microscope of a DNA  microarray slide Figure 3
Image from laser scanning confocal microscope of a DNA 
microarray slide. mRNA, is extracted from a sample and a 
control and after its transcription into more stable cDNA, 
one is labeled with cy-5 (red fluorescent dye) and the other 
with cy-3 (green fluorescent dye). The two cDNA popula-
tions are allowed to hybridize to the same microarray slide. If 
particular mRNA from the sample is in abundance, the spot 
with a complementary probe will be red (induction of gene 
expression in sample condition); if the concentration of the 
particular mRNA is higher in the control, the spot will be 
green (induction of gene expression in control condition). If 
both samples contain the same amount of a given mRNA the 
spot will be yellow (equal gene expression in both condi-
tions). (Adapted with permission of Dr Karameris Andreas.)Respiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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methods. Nevertheless apparent inconsistencies with the
gene expression pattern revealed by Kaminski et al. [23]
highlight the inability of microarray approach in distin-
guishing changes in transcriptional regulation from
changes in cellular composition of the organ being stud-
ied. Thus, it is likely these discrepancies between findings
of the two studies to represent differences in cellular com-
position, rather than differences in transcriptional
regulation.
One of the most informative studies scrutinizing the glo-
bal gene expression profile of fibroblasts in response to
one of their most potent activators, TGF-β1, has been pub-
lished by Chambers et al. [25] Gene expression analysis of
human lung fibroblasts treated with TGF-β1 has led inves-
tigators to uncover novel TGF-β1-inducible genes includ-
ing genes encoding inhibitors of differentiation (ID) as
well as genes that are usually expressed by highly differen-
tiated smooth muscle cells. The induction of these genes
was further confirmed at the mRNA level (Northern blot
analysis) and the protein level (Western blot analysis) for
primary cultures of adult lung fibroblasts. The potential
relevance of these observations in vivo was established in
a separate set of confirmational experiments in rats where
it was revealed an overexpression of the ID by myofibrob-
lasts within the fibrotic regions. These novel suggestions
have major impact on our understanding of the crucial
role of TGF-β1 as a fibroblast differentiation factor in
response to fibrogenic stimuli. Nonetheless the present
study does not determine the precise role of ID in regulat-
ing fibroblast responses to TGF-β1. To do so this study
should be coupled with independent methods using ID
blocking strategies. Moreover the use of incomplete arrays
that detect only the included genes, the variability of cel-
lular composition of tissues studied even from the same
organ and the inability of this technology to distinguish
changes in cellular composition from transcriptional
changes pose major limitations to the global application
of these results. Furthermore these observations offer
plausible explanations for the lack of similar effects of
TGF-β1 in previous studies.
Moreover, bleomycin-induced pulmonary fibrosis rat
model was extensively studied by Liu et al. [26] with the
use of rat cDNA microarray platforms, in an attempt to
highlight genes that may be involved in fibrosis. Interest-
ingly a novel and unexpected finding of this microarray
analysis was the identification of FIZZ1 as the most highly
and prominently induced gene in bleomycin-treated
lungs, evidence consistent with the RT-PCR results. Fur-
ther analysis of its protein product, demonstrated a
unique pattern of localization primarily to alveolar
Table 1: Studies utilizing microarray technology to analyze IPF
Investigator Microarray type Species/Sample size Summary/Key findings Normalization procedure
Number of genes Type of tissue Replications per data point
Zuo et al.22 Oligonucleotide 8.400 
genes
5 patients with IPF Lung 
tissue specimens
Gene expression analysis 
reveals matrilysin as a key 
regulator of PF in mice and 
humans.
Gene expression levels 
normalized by a scaling 
factor multiplied to the 
average of differences of 
probe pairs (matched-
mismatched) / 2 replicates
Kaminski et al.23 Oligonucleotide 6.000 
genes
30 mice Lung tissue 
specimens
Global analysis of gene 
expression in PF reveals 
distinct programs 
regulating lung 
inflammation and fibrosis.
Mean hybridization 
intensities of all probe sets 
on each array were scaled 
to an arbitrary, fixed level/4 
replicates
Katsuma et al. 24 cDNA 4.224 genes 22 mice Lung tissue 
samples
Molecular monitoring of 
bleomycin-induced 
pulmonary fibrosis by 
cDNA microarray-based 
gene expression profiling.
Quantified signal intensities 
were converted by 
logarithms of base two 4 
replicates
Chambers et al. 25 Oligonucleotide 6.000 
genes
Human lung fibroblasts Global expression profiling 
of fibroblast responses to 
transforming growth 
factor-beta1 reveals the 
induction of ID1.
Gene expression levels 
normalized by a scaling 
factor multiplied to the 
average of differences of 
probe pairs (matched-
mismatched)/ 2 replicates
Liu et al.26 cDNA 10.000 genes 12 rats Lung tissue 
specimens
FIZZ1 stimulation of 
myofibroblast 
differentiation.
Average median ratios 
Cy3/Cy5 values normalized 
to 1.0/ 4 replicates
Abbreviations: ID: Inhibitor of Differentiation, IPF: Idiopathic Pulmonary Fibrosis, PF: Pulmonary FibrosisRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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epithelial cells (AECs) derived from bleomycin-injured
lungs. To illuminate the exact role of FIZZ1 in inflamma-
tion and fibrosis, the effects of co-culturing FIZZ1-express-
ing AECs on fibroblasts were examined. These analyses
demonstrated the significant higher stimulation of nor-
mal lung fibroblasts, by high FIZZ1-expressing-AECs, as
compared to that observed by control AECs. The major
contribution of this new molecule in the differentiation of
fibroblasts to myofibroblasts was suggested and verified
by its transfection into normal lung fibroblasts which pro-
voked their stimulation independently of TGF-β
activation.
These preliminary results suggest that this technology
could identify unexpected molecular participants in IPF
and might help in the development of novel targets for
improved treatment. The method may also allow molecu-
lar fingerprinting that could improve the ability to iden-
tify subclassifications of pulmonary fibrosis that might be
more informative than the current classification based pri-
marily on histologic and radiographic patterns [27].
Nonetheless these studies characterized as "fishing expe-
ditions" are limited by the inability of microarrays to
detect the final expression product (protein), identify
genes that are not included in the array and ascribe
changes in gene expression in specific cellular types. How-
ever our view is that there is nothing wrong with a "fishing
expedition" if what you are after is "fish", such as new
genes involved in a pathway, potential drug targets or
expression markers that can be used in predictive or diag-
nostic fashion. Hence, these observations are not to
diminish their value for understanding basic biological
processes and even for understanding, predicting and
eventually treating human disease (Table 1).
2. Microarrays in asthma (Tables 2 and 3)
Asthma is one of the most serious allergic diseases associ-
ated with both genetic and environmental factors such as
allergens, respiratory tract infections, and atmospheric
pollutants. Most asthma is associated with atopy, a predis-
position to generate immunoglobulin (Ig)-E against envi-
ronmental allergens [28]. However, only a proportion of
atopic individuals develop lower airways symptoms con-
sistent with an asthmatic phenotype. It is therefore tempt-
ing to speculate that the development of asthma requires
combined inheritance of genes which alter the immune
cell response to the environment, and at the same time,
render the airways structural and neural regulation
susceptible to injury caused by inflammation. Several
asthma/atopy associated genes have been identified from
Table 2: Studies utilizing cDNA microarray technology to study asthma
Investigator Microarray type Species/Sample size Summary/Key findings Normalization procedure
Number of genes Type of tissue Replications per data point
Zou et al.32 cDNA 40.000 elements 10 monkeys Lung tissue 
samples
Microarray profile of 
differentially expressed 
genes in a monkey model 
of allergic asthma.
Ratios of Cy5/Cy3 
multiplied to the balance 
coefficient of the 
microarray / 3 replicates
Brutsche et al.33 cDNA 600 genes 40 subjects Mononuclear 
cells
CAGE score for atopy and 
asthma.
Absolute difference of the 
expression of CAGE 
scored genes 1 replicate
Sayama et al.38 cDNA 14.000 genes human umbilical cord mast 
cells
Transcriptional response of 
human mast cells 
stimulated via the Fc 
(epsilon) RI and 
identification of mast cells 
as a source of IL-11.
Array-specific 
normalization coefficient 
was calculated by centering 
in log base 2 space a 
dataset consisting of all 
elements with an I/D> 3-
fold / 2 replicates
Brutsche et al.41 cDNA 600 genes 40 subjects Mononuclear 
cells
Apoptosis signals in atopy 
and asthma measured with 
cDNA arrays
G.I was normalized to the 
housekeeping G.I / 1 
replicate
Syed et al. 42 cDNA 12.228 genes Human CD4+ T cells CCR7 down-regulation in 
asthma
Median G.I of each filter 
normalized any differences 
in cDNA probe activity 
between filters/ 1 replicate
Banerjee et al.43 cDNA 1.176 genes 18 mice Lung tissue 
samples
Gene expression profiling 
in inflammatory airway 
disease associated with 
elevated adenosine
G.I was normalized to the 
housekeeping G.I / 2 
replicates
Abbreviations: CAGE: Composite atopy gene expression, CCR7: Chemokine receptor 7, G.I: Gene Intensity, I/D: Intensity/Background ratio, Th: T 
helper, RI: Immunoglobulin receptorRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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linkage and association studies within families and
revealed that there are multiple chromosomal regions,
containing potential candidate genes, associated with var-
ious asthma phenotypes [29-31].
Microarray technology offers a new opportunity to gain
insight into global gene expression profiles in asthma,
leading to the identification of asthma associated genes.
Several experimental models have been used for this pur-
pose although no animal disease model is identical to
human disease. Zou et al.[32] were the first attempted to
produce an allergen-induced gene expression profile in
the lung of a non-human primate using genomics tools
such as microarrays and real time-(RT)-PCR in an inde-
pendent way. Microarray data generated from this study
and validated by RT-PCR using same lung samples,
revealed a differential gene expression pattern between
control and challenged animals. Furthermore investiga-
tors established that genes identified by microarray
technology represented genes truly regulated by inhala-
tion antigen challenge. This was done by determining that
the regulated expression levels identified by microarray
assay from a single animal were confirmed by RT-PCR
studies using multiple similarly treated animals. Potential
limitations of this study include the time-limited gene
expression profile tested which may not reflect the chronic
aspect of asthma and the absence of evidence that the
antigens used would produce the same allergic reaction in
humans.
Brutsche et al. [33] designed an array based composite
atopy gene expression (CAGE) score to evaluate the diag-
nosis of atopy and asthma and assess disease activity in
order to guide therapeutic decisions. The CAGE score was
determined by using 10 genes dysregulated atopic indi-
viduals according to a specific algorithm. The application
of this score in a group of asthmatic patients revealed that
this approach had a better sensitivity and specificity than
total IgE in differentiating atopic from non-atopic sub-
jects. Correlation between CAGE score and total IgE was
found, and there was a trend for correlation with asthma
severity. It is noteworthy that the CAGE score was able to
quantify phenotype-specific alteration in gene expression
of atopic individuals. Perspectively the CAGE score can be
further improved through a better reproducibility of
microarray systems compared with the filter arrays and
the possibility of a better selection of genes. Therefore it
may be used as a prognostic and diagnostic tool or to
Table 3: Studies utilizing oligonucleotide microarray technology to study asthma
Investigator Microarray type Species/Sample size Summary/Key findings Normalization procedure
Number of genes Type of tissue Replications per data point
Lee et al.34 Oligonucleotide 6.500 
genes
Human airway cells IL-13 induces dramatically 
different transcriptional 
programs in three human 
airway cell types.
Gene expression levels 
normalized by a scaling 
factor multiplied to the 
average of differences of 
probe pairs (matched-
mismatched)/ 1 replicate
Temple et al.35 Oligonucleotide 6800 
genes
Human eosinophils Microarray analysis of 
eosinophils reveals a 
number of candidate 
survival and apoptosis 
genes.
Geometric mean of the 
scaling (standard 
experiment) factor served 
as normalization factor/ 2 
replicates
Hakonarson et al.36 Oligonucleotide 5.000 
genes
Rabbit and human ASM Association between IL-
1beta/TNF-alpha-induced 
glucocorticoid-sensitive 
changes in multiple gene 
expression and altered 
responsiveness in ASM.
Gene expression levels 
normalized by a scaling 
factor multiplied to the 
average of differences of 
probe pairs (matched-
mismatched) / 2 replicates
Laprise et al.37 Oligonucleotide 12.000 
probe sets
8 subjects Lung tissue 
samples
Functional classes of 
bronchial mucosa genes 
that are differentially 
expressed in asthma.
Mean hybridization 
intensities of all probe sets 
on each array were scaled 
to a fixed level/ 2 replicates
Nakajima et al.39 Oligonucleotide 12.000 
genes
Human MCs and 
eosinophils
Gene expression screening 
of human mast cells and 
eosinophils using high-
density oligonucleotide 
probe arrays: abundant 
expression of MBP in MCs
Mean hybridization 
intensities of all probe sets 
on each array were scaled 
to an arbitrary, fixed level / 
1 replicate
Abbreviations: ASM: Airway Smooth Muscle cells, MBP: Major Basic Protein, MCs: Mast cells, TNF: Tumor Necrosis FactorRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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monitor the effects and side-effects of asthmatic therapy
in the not distant future.
Several morphologic changes in the airways of patients
with asthma have been attributed to the Th-2 produced
cytokines such as IL-13 and IL-5. However the molecular
mechanisms underlying the contributions of these
cytokines to asthma remain largely unknown.
Towards this direction Lee et al. [34] applied oligonucle-
otide microarray technology in primary cultures of three
human airway cell types (epithelial, smooth muscle cells
and lung fibroblasts) to elucidate the effects of IL-13 in
these cell types. Interestingly, the results of this study
demonstrated that despite initiation of an identical sign-
aling pathway (STAT6), IL-13 induced highly distinct
transcriptional programs in each of the three cell types
suggesting a coordinate and distinct contribution to
asthma pathogenesis by each of the cell types examined.
Although the quality of the genechip analysis was esti-
mated and validated by RT-PCR methods applied in a
small number of selective genes, however there are impor-
tant limitations in this study including the possible differ-
ences between transcriptional responses and gene
expression profile of a cell type in vivo and in vitro.
One of the greatest disadvantages of microarrays and at
the same time challenges for most of the investigators is
the objective difficulty dealing with the results of the
experiments resulting from the large quantities of infor-
mation. Currently, the hurdle faced is the routine
interpretation of this information to identify among thou-
sands of dysregulated genes, those who are informative,
causal and specific to the phenotypic change of interest.
Thus, Temple et al. [35] compared the results derived
from the application of oligonucleotide microarray tech-
nology in eosinophils isolated from human peripheral
blood before and after treatment with IL-5 and in an alter-
native cellular model, TF1.8 cells, whose survival was
known to be dependent on IL-5. Comparison of these two
models facilitated the identification of the genes that rule
the apoptosis and survivability of eosinophils and dem-
onstrated a small group of genes whose regulation was
similarly coordinated in both systems. Authors combined
different cellular models focused on the same
experimental paradigm and looked for common changes.
This approach helped the scientists to focus attention on
a subset of genes most likely to be causal and relevant to
the phenotypic change of interest and filter out non-spe-
cific gene expression change. Combination of this method
with proteomics approaches and tissue distribution anal-
ysis can add another filter for genes of interest and gener-
ate data of sufficient scientific rigidity.
Microarrays apart from their remarkable effectiveness in
identifying novel gene expression patterns can also be
used to clarify physiological mechanisms underlying the
actions of numerous drugs, such as those applied in the
management of patients with asthma. Several studies have
utilized microarray technology to assess the gene expres-
sion profile of cells and tissues before and after treatment
with commonly applied drugs such as corticosteroids.
Two of them are reviewed here.
Recently, Hakonarson et al. [36] in addition with the role
of two pleiotropic cytokines, IL-1β and tumor necrosis
factor (TNF)-α, in the pathophysiology of asthma, have
reported the effectiveness of dexamethasone in the treat-
ment of asthma with the use of oligonucleotide microar-
rays. The accumulation of the two cytokines in a medium
where human airway smooth muscle-(ASM) – cells were
cultured, elicited an overexpression of several proinflam-
matory genes known to regulate smooth muscle contrac-
tility and relaxation. The latter finding noted in four
separate microarray experiments was consistent with the
increased responsiveness of rabbit cytokine-treated tissues
in acetylcholine. The administration of dexamethasone
provoked a repression to the majority of the microarray-
study derived genes as well as to the contractility of the
cytokine-treated ASM. Collectively these findings suggest
a crucial role of ASM in expressing a host of glucocorti-
coid-sensitive proinflammatory gene patterns that affect
the structure and the function of the airways. However
these observations were based on studies using rabbit and
human ASM cells. Hence the issue of potential species dif-
ferences warrants consideration. Further studies using
samples derived from homogeneous species and valida-
tion techniques are necessary to streamline these
observations.
Microarray analysis performed by Laprise et al. [37] indi-
cated a differential gene expression pattern in bronchial
tissues from healthy and asthmatic individuals, a profile
that included not only genes previously implicated in the
pathogenesis of asthma but also new potential candi-
dates. The remarkable ascertainment of this study, con-
ducted with bronchial tissues which are known as a
primary site for airway inflammation and remodeling,
was that the expression of one third of the genes was par-
tially or completely corrected by inhaled corticosteroid
treatment. The latter evidence further illuminates the true
impact of first line therapy offered to asthmatic patients.
However application of this technology may be limited by
the disease's spatial and temporal heterogeneity due to
differences in cellular composition between asthmatic
and control tissue. Ultimately the results obtained using
microarrays need to be verified firstly with confirmational
studies (RT-PCR and in situ hybridization) and secondly
with separate experiments.Respiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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Mast cells represent key cells in the initiation and progres-
sion of asthma, releasing several mediators of inflamma-
tion, such as certain cytokines and chemokines. The past
few years several studies have been focused on the identi-
fication of new mast cell products through the gene
expression analysis. In one of them published by Sayama
et al. [38] application of cDNA microarrays in only two
populations of stimulated human mast cells exhibited
among other genes a significant upregulation of the gene
encoding IL-11. The latter finding was further confirmed
by a separate set of experiments where an increased secre-
tion of IL-11 by activated human mast cells was noted.
However further microarray analyses coupled with func-
tional approaches and independent studies examining the
potential role of IL-11 in the pathogenetic mechanisms of
asthma as well as in the alterations of mast cell prolifera-
tion and survival, are required.
Furthermore, Nakajima et al. [39] in their attempt to eval-
uate the significance of protein products present in mast
cells applied oligonucleotide microarray technology in
human mast cells derived from different sources and in
eosinophils. The most impressive finding of this study
was the abundant expression of major basic protein
(MBP) among the transcripts for expected mast cells spe-
cific proteins such as tryptase. Authors also confirmed in
independent studies using RT-PCR and flow cytometry
that MBP was expressed at both the transcript and protein
levels in various types of mast cells. While this result is
really intriguing and opposes to the already known data
which indicates the unique presence of MBP to eosi-
nophils [40], it is incomplete and unable to determine the
biologic significance of MBP present in mast cells.
Microarrays using nylon membrane radioactive cDNAs
have already been applied in the research field of asthma
and much good work has been done with this technology.
Brutsche et al. [41] applied nylon membrane cDNA
microarray technology in blood samples derived from
atopic asthmatic and nonasthmatic patients, and healthy
control subjects to investigate the systemic activation of
apoptosis pathways of inflammatory cells in lung tissue.
They identified significantly altered expression of several
apoptosis-related genes in atopy and asthma compared
with the healthy subjects suggesting that these alterations
could be due to genetic or environmental factors. Several
verification experiments have been used to further vali-
date a considerable amount of differentially expressed
genes on mRNA level (RT-PCR), as well as protein (ELISA)
and receptor level (double stained fluorescence methods).
The profile of altered gene expression did not show a def-
inite pattern that was suggestive of survival or apoptosis.
Potential criticisms of this approach include the large
amounts of data variability derived from the heterogene-
ity of the studied samples and the lack of proteomics anal-
yses. Thus this study is unable to give any statement on the
activity of the apoptotic pathways. To do so the data
should be combined with the proteomics analysis of pro-
teins involved in apoptosis. The latter will contribute to
the characterization of protein patterns and will allow for
the assessment of overall changes in the protein content
associated with apoptosis.
One of the first gene-profiling studies highlighting the
potential role of chemokines and their receptors in the
pathogenesis of asthma was conducted by Syed et al. [42]
They used nylon membrane radioactive arrays compiled
from mixed biological samples to determine the gene
expression pattern of T-cells from patients with atopic and
non-atopic asthma and found altered gene expression
profile for CCR7 (chemokine receptor 7) between
patients and controls, findings that were confirmed by
RNA dot plot analysis. Data derived from this analysis is
indicative of a possible role of this molecule in the pro-
gression of asthma. However the small number of patients
recruited in this study and the lack of functional genomic
analysis allow us to make only speculations on the exact
role of this factor in the disease process.
In another study Banerjee et al. [43] in their attempt to
identify and characterize biological roles for adenosine-
regulated genes applied radioactive cDNA microarray
technology in lung specimens derived from normal and
adenosine deaminase (ADA)-deficient mice. The results of
this study profile the differential expression of a vast
number of genes, that may be regulated by adenosine and
hence play a pivotal role in modulating the underlying
lung pathology. The reliability of the results derived from
the microarray approach was also confirmed with gene
specific RT-PCR analysis. Moreover authors used a sepa-
rate set of experiments and demonstrated both with
microarray analysis and protein localization that therapy
with ADA in the deficient group of mice regulated expres-
sion of several genes modulating pulmonary inflamma-
tion and cell adhesion. The consistency of findings
derived from the two experiments provides to microarray
analysis a high degree of confidence. However critical
limitations of this study originate from the disability of
gene expression analysis to distinguish changes in tran-
scriptional regulation from changes in cellular
composition. Hence a more in-depth analysis is required
to quantify the gene expression and establish a direct reg-
ulation of these genes by adenosine signaling.
Accumulated evidence from these analyses revealed that
microarray analysis can be a powerful tool for identifying
mediators of allergic asthmatic disease through a
genomic-based strategy using non-human primates and
provide us a novel large scale of differentially expressedRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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genes. Additionally, authors compared different cellular
models sharing similar experimental paradigm to focus
on the most likely informative genes and filter out the
bystanders. The application of this approach further
streamlined the pivotal role of microarrays in determining
transcriptional responses of genes to several inflammatory
cytokines and in identifying gene expression patterns and
important mediators associated with the initiation and
the progression of asthma. Moreover, microarrays cou-
pled with separate set of experiments have provided the
investigators with useful knowledge concerning the effi-
cacy of the already applied drugs in the treatment of
asthma and helped them to understand their anti-inflam-
matory role in terms of physiology and molecular biol-
ogy. Nevertheless, most of the studies exhibited essential
weaknesses generated by the heterogeneity of samples
studied and compared and by the disability of microar-
rays to quantify gene expression and yield information
about transcriptional responses and post-translational
protein modifications. Therefore more in depth analysis
of the microarray results is needed in combination with
novel approaches that will help us focus on the specific
genes and elucidate their role in the cellular function and
the pathogenesis of asthma (Tables 2,3).
3. Microarrays in Chronic Obstructive Pulmonary Disease (Table 4)
Chronic obstructive pulmonary disease (COPD) is a
chronic disease characterized by progressive airflow
obstruction, chronic cough and dyspnea in advanced
stages, caused by smoking, environmental, and hereditary
factors. It is associated with two clinical entities, chronic
bronchitis and emphysema. In nowadays, the invention
Table 4: Studies utilizing microarray technology to study COPD
Investigator Microarray type Species/Sample size Summary/Key findings Normalization procedure
Number of genes Type of tissue Replications per data point
Koike et al.45 cDNA 450 genes Rats AM cDNA microarray analysis 
of gene expression in rat 
alveolar macrophages in 
response to organic 
extract of diesel exhausts 
particles.
G.I was normalized to the 
housekeeping G.I 2 
replicates
Yamanaka et al.46 cDNA 18.432 genes Human AEC Gene expression profiles 
of human small airway 
epithelial cells treated with 
low doses of 14- and 16-
membered macrolides.
G.I was normalized to the 
housekeeping G.I 3 
replicates
Fuke et al.47 cDNA 77 genes 30 patients Lung tissue 
specimens
Chemokines in bronchiolar 
epithelium in the 
development of chronic 
obstructive pulmonary 
disease.
Signal normalized to a given 
gene transcript 3 replicates
Vuillemenot et al.48 Oligonucleotide 12.000 
genes
10 mice Lung tissue 
specimens
Lymphoid tissue and 
emphysema in the lungs of 
transgenic mice inducibly 
expressing tumor necrosis 
factor-alpha.
Signal normalized to 
internal control 2 
replicates
Hackett et al.50 cDNA 4.600 genes 22 individuals AEC Variability of antioxidant-
related gene expression in 
the airway epithelium of 
cigarette smokers.
Mean hybridization 
intensities of all probe sets 
on each array were scaled 
to an arbitrary, fixed level / 
2 replicates
Morris et al.52 Oligonucleotide 6.500 
genes
Mice Lung tissue samples Loss of integrin alpha (v) 
beta6-mediated TGF-beta 
activation causes MMP-12-
dependent emphysema.
Mean hybridization 
intensities of all probe sets 
on each array were scaled 
to an arbitrary, fixed level / 
2 replicates
Golpon et al.53 Oligonucleotide 6.500 
genes
Human/mice Lung tissue 
samples
HOX genes in human lung: 
altered expression in 
primary pulmonary 
hypertension and 
emphysema.
Gene expression levels 
normalized by a scaling 
factor multiplied to the 
average of differences of 
probe pairs/ 3 replicates
Abbreviations: AEC: Airway Epithelial Cells, AM: Alveolar Macrophages, COPD: Chronic Obstructive Pulmonary Disease, G.I: Gene Intensity, TGF-
b: Transforming Growth Factor-beta, MMP: MetalloproteinaseRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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and application of microarray technology offers scientists
the opportunity to gain a better understanding on the
pathophysiology of COPD through the identification of
novel gene expression patterns, leading to illumination of
genes candidates for modern therapeutical approaches
[44].
It is already known that chronic bronchitis can be induced
by several types of environmental pollutants such as
diesel exhaust particles (DEP). Though recently a microar-
ray study has been published by Koike et al. [45] address-
ing the effect of such pollutants on the gene expression
profiles of alveolar macrophages, however a complete
analysis including the transcriptome and proteome, is
needed to elucidate the toxic effect of air pollutants on
pulmonary cells.
Microarray approach is already being applied in respira-
tory clinical pharmacology with the identification of
genes {Yamanaka et al. [46]} that can serve as potential
molecular targets of common drugs applied in the man-
agement of patients with chronic bronchitis. However,
studies being published in the field of respiratory pharma-
cogenomics lack of scientific rigidity primarily due to
incomplete available arrays that will help scientists to
determine much larger numbers of pharmacologically rel-
evant genotypes. Far more progress should be made
towards this direction.
One of the major limitations in our attempt to elucidate
the exact role of specific cell types in the pathogenesis of
COPD is the compact anatomy of the lung which makes
unraveling specific cell type gene expression changes diffi-
cult, requiring immunoelectron microscopy or laser cap-
ture microdissection. The first study to perform
quantitative cell type-specific gene expression analysis
using the pioneering technology of laser capture microdis-
section in human tissue samples coupled with RT-PCR
and cDNA approach was recently published by Fuke et al.
[47] Authors performed individual analyses and revealed
a specific cell type upregulation of three inflammatory
chemokines reportedly relevant to the pathogenesis of
COPD emphasizing the pivotal role of these cells and
their products in driving the inflammation. Although data
was not fully confirmed by microarray analysis, however
discrepancies between methods illustrate more the poten-
tial danger of depending solely on array approach rather
than limit the scientific consistency of these results.
Further research investigating the functional conse-
quences of these changes is required.
Several inflammatory cytokines have been implicated in
the pathogenesis of emphysema, including TNFa, a mole-
cule with versatile pathogenetic mechanisms. As a means
to investigate some of them that culminate to lung-
pathology, Vuillemenot et al. [48] applied oligonucle-
otide microarray technology coupled with independent
studies (histologic and immunohistochemical analyses)
in an experimental model they developed. Results derived
both by microarray approach and independent studies
revealed a direct correlation between TNFa and emphy-
sema. However functional approaches should be applied
in combination with gene expression analysis to shed fur-
ther light in the mechanisms by which TNF promotes air-
space enlargement.
Despite the clear link of smoking to the risk for chronic
bronchitis, only 15–20% of cigarette smokers develop
COPD, [49] suggesting that there must be risk factors
other than smoking that contribute to the susceptibility to
this disease. To address this issue Hackett et al. [50] imple-
mented microarray technology in human airway epithe-
lial cells of smokers and non-smokers and demonstrated
differential anti-oxidant related gene expression between
the two groups of volunteers. One of the most intriguing
aspects of this study is that individual assessment by hier-
archical clustering of anti-oxidant related gene expression
in response to smoking displayed a remarkable variability
suggesting variability in the responses of different individ-
uals to the chronic oxidant stress of smoking. However the
extent of this variability may be explained by the nature of
the microarray assay and the large amounts of data varia-
tion derived from these studies. Thus it is of high risk to
speculate that these genes may serve as useful genetic
markers in future epidemiologic studies determining sus-
ceptibility to smoking induced COPD. Further studies
applying high-tech computational clustering tools cou-
pled with independent validation tests are required.
One of the most exciting aspects of microarrays is their use
as tools for actively introducing serendipity to one's
research [51]. In experiments designed to identify global
transcriptional programs responsible for regulating lung
inflammation and pulmonary fibrosis, as described previ-
ously, [23] microarray experiments were performed by
Morris et al. [52] on lung tissue from wild-type mice and
mice lacking a member of the integrin family (avβ6)
known to be involved in activation of latent TGF-β. In
addition to identifying distinct cluster of genes involved
in these processes, these studies combined with RT-PCR
validation tests and independent experiments led to the
identification of novel pathways by which TGF-β can reg-
ulate emphysema through the upregulation of Mmp-12,
the most highly induced gene in the lungs of β6 knockout
mice. The role of Mmp-12 in the pathogenesis of emphy-
sema was verified in an independent cohort where β6
knockout mice deficient in the expression of Mmp-12 dis-
played no alveolar enlargement. Although these results do
not eliminate the possibility that other proteases may
interact with Mmp-12 in the development of emphysema,Respiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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however suggest that abnormalities in any of the steps in
this pathway of TGF-β activation may contribute to
genetic or acquired susceptibility to emphysema in
humans.
Presently, very few studies dealing with the role of HOX
genes in the adult respiratory system are available in the
literature. Golpon et al. [53] investigated the expression
pattern of HOX genes, in fetal and diseased lung speci-
mens (emphysema, primary pulmonary hypertension),
by applying two microarray survey techniques and their
analysis reflects one of the most detailed and informative
studies in this field. They compared the HOX gene expres-
sion pattern in human and mouse lungs and found that
HOX genes are selectively expressed in the human lung.
This study also yielded an altered HOX-gene expression
pattern among fetal, adult and lung specimens with
emphysema and pulmonary hypertension, by identifying
different types of HOX genes overexpressed in each of
these conditions indicating differential HOX gene expres-
sion as a potential factor that contributes to the develop-
ment of certain pulmonary diseases. Though the overall
size of tissue samples studied was small data from this
study comprises evidence with high degree of confidence,
validated and confirmed both in an independent cohort
(degenerate RT-PCR) and by alternative methods (quanti-
tative RT-PCR and in situ hybridization). Possible limita-
tions include small number of tissues studied, incomplete
microarray survey techniques and minor discrepancies
between the findings generated from validation studies.
Collectively these results suggest that microarray analysis
with its ability to highlight gene expression profiles on a
large scale and coupled with progressive technologies and
independently validated data has led researchers to shed
further light into transcriptional programs regulating
emphysema and to the identification of common media-
tors and molecular pathways involved in the pathogenesis
of both COPD and pulmonary fibrosis, indicating novel
targets for therapeutic interventions and useful genetic
markers assessing susceptibility to COPD. Although limi-
tations such as inconsistency between findings derived by
microarray approach and independent studies, lack of
functional changes assessment and significant data varia-
bility can be detectable in these studies, however evidence
derived from these analyses is valuable and heavily
informative (Table 4).
4. Microarrays in acute lung injury and pulmonary edema (Table 5)
Acute lung injury (ALI), a severe respiratory syndrome,
develops in response to numerous insults. This syndrome
that responds poorly in therapeutic interventions and has
a poor prognosis has been associated with a myriad of
mediators including cytokines, reactive oxygen and nitro-
gen species, growth factors and proteolytic enzymes
[54,55]. Despite extensive research since the initial
description of ALI over 30 yr ago, questions remain about
the basic pathophysiologic mechanisms that are critical to
the diminished survival and their relationship to thera-
peutic strategies. McDowell et al. [56] in their attempt to
determine the interactions between the great amount of
factors that have been associated with the development of
ALI, analyzed 8,374 murine cDNAs for temporal changes
and functional relationships throughout the initiation
and progression of ALI in mice exposed to particulate
NiSO4. Novel interactions between factors (antioxidant
genes) previously associated with ALI and factors (sur-
factant proteins) previously not associated with ALI
emerged from the application of functional genomics dur-
ing nickel-induced ALI. Data derived from this experiment
and partially confirmed by Northern blot analysis and
nuclease protection assays is valuable and consistent with
the ongoing attempts to treat ALI with exogenous sur-
factant-associated proteins [57] in combination with anti-
oxidant therapy and may determine new therapeutical
interventions. This study reveals the great importance of
functional genomics not simply to provide a catalogue of
all the genes and information about their functions, but to
help scientists to understand the possible interplay of
components contributing to lung injury.
Although the fibroproliferative response to lung injury
occurs in high frequency in patients with ALI, the
mechanisms of this response are largely unknown. One of
the most meaningful and informative studies addressing
this important issue was recently published by Olman et
al [58]. Authors applied radioactively nylon membrane
arrays in human lung fibroblasts exposed either to ALI or
hydrostatic pulmonary edema fluids and revealed a
potential mitogenic activity of IL-1β and its importance as
a modulator of fibroblast proliferation. Data derived from
this study of a considerable number of patients and repli-
cated both in an independent cohort (use of IL-1 antago-
nist receptor) and by alternative laboratory methods (RT-
PCR, Northern blot analysis) is of fundamental value and
may provide scientists with several independent lines of
evidence that IL-1 amplifies the inflammatory and fibro-
proliferative process through regulation of fibroblast
mitogenesis and gene expression. A major limitation
mentioned in this study was the pooling of pulmonary
edema samples due to their limited volume that did not
allow authors to perform clinical-molecular correlations
in an individual way.
ALI is frequently associated with endotoxemia and is char-
acterized by the accumulation in the lungs of large
populations of neutrophils activated to produce proin-
flammatory mediators. Many studies had demonstrated a
critical role of the endotoxemia-induced activation of NF-
κB in neutrophils in the development of ALI [59,60]. OneRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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of the most important studies focused on the role of NF-
κB activation in lung neutrophils apoptosis after endotox-
emia was conducted by Kupfner et al. [61]. Though gene
expression analysis revealed a significant role of NF-κB as
a modulator of neutrophil apoptosis and data was con-
firmed by proteomics analysis there were major discrep-
ancies between these findings and the results derived from
individual experiments utilizing an inhibitor of nuclear
translocation of NF-κB. The latter demonstrated no signif-
icant alterations in the percentage of the endotoxemia -
induced apoptotic lung neutrophils in mice treated with
the inhibitor evidence that reflects anti-apoptotic mecha-
nisms not solely dependent on NF-κB. Although these
findings can be informative indicating novel anti-apop-
totic pathways for modern therapeutic approaches they
should be re-evaluated in the context of new microarrays
analyses of considerable sample size coupled with confi-
dent validation steps and independent experiments.
To gain a more comprehensive understanding on the
complex interplay between several inflammatory
cytokines involved in the pathogenesis of pulmonary
edema, several group of investigators {Cher et al. [62],
Sabbadini et al.[63]} applied oligonucleotide microarray
techniques in different experimental models of lung
edema. Interestingly, these analyses revealed differential
expression patterns for many inflammatory genes impli-
cating some of them in the pathogenesis of pulmonary
edema. Though these studies applied several confirma-
tional tests (RT-PCR, Northern blot, Western blot) to val-
idate results derived form microarray experiments, there
are substantial weaknesses and concerns such as discrep-
ancies between findings determined by these techniques
that pose major limitations and limit their scientific
rigidity.
The study of Perkowski et al. [64] has been on of the most
extensive and informative studies of the effect of 100%
Table 5: Studies utilizing microarray technology to study ALI/PE
Investigator Microarray type Species/Sample size Summary/Key findings Normalization procedure
Number of genes Type of tissue Replications per data point
McDowell et al.56 cDNA 8.374 genes 6 mice Lung tissue samples Differential gene 
expression in the initiation 
and progression of nickel-
induced ALI.
Ratios of Cy5/Cy3 
multiplied to the balance 
coefficient of each 
microarray / 5 replicates
Olman et al.58 cDNA 588 genes 36 patients Pulmonary 
edema Lung fibroblasts
Microarray analysis 
indicates that pulmonary 
edema fluid from patients 
with ALI mediates 
inflammation, mitogen gene 
expression, and fibroblast 
proliferation through 
bioactive IL-1.
G.I normalized to the 
housekeeping G.I 2 
replicates
Kupfner et al.61 Oligonucleotide Mice Lung neutrophils Role of NF-κB in 
endotoxemia-induced 
alterations of lung 
neutrophil apoptosis.
Gene expression levels 
normalized by a scaling 
factor multiplied to the 
average of differences of 
probe pairs / 3 replicates
Cher et al.62 Oligonucleotide 8.800 
genes
21 rats Whole lungs Pulmonary inflammation 
and edema induced by 
Phospholipase A2.
Each gene was divided by 
the median of its values in 
all samples / 3 replicates
Sabbadini et al.63 Oligonucleotide 12.600 
genes
14 rabbits Lung tissue 
samples
Gene expression analysis in 
interstitial lung edema 
induced by saline infusion.
Gene expression levels 
normalized by a scaling 
factor multiplied to the 
average of differences of 
probe pairs / 2 replicates
Perkowski et al.64 cDNA 8.374 genes 20 mice Lung tissue 
samples
Gene expression profiling 
of the early pulmonary 
response to hyperoxia in 
mice.
Difference between 
observed log-ratio and 
corresponding fitted ratio/ 
5 replicates
Ward et al.65 cDNA 7.398 genes 6 rats Lung and other 
organ samples
Molecular signatures of 
sepsis: multiorgan gene 
expression profiles of 
systemic inflammation.
Gene expression levels 
normalized by a scaling 
factor multiplied to the 
average of differences of 
probe pairs / 4 replicates
Abbreviations: ALI: Acute Lung Injury, G.I: Gene Intensity, PE: Pulmonary Edema, NF-κB: Nucleus Factor-κBRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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oxygen on the mouse lung. The authors used the cDNA
microarray approach to evaluate the molecular profiling
occurring during the early response to hyperoxia in mice.
Among the vast amount of data derived from two differ-
ent array sets they distinguished a cluster of genes of great
interest (antioxidant enzymes, cell cycle progression regu-
lators, endothelial cell and ECM genes) whose expression
was substantially altered in response to hyperoxic stimuli.
Authors were encouraged to observe that, of those genes
where array data was compared with RT-PCR, changes
occurred in same direction and were of similar
magnitude. Further validation of the data with Northern-
blot analysis for some of these genes reassuringly con-
firmed these alterations whereas for only one gene inves-
tigators performed functional activity assessment
demonstrating similar notable findings. Though the
results of this microarray study were double validated by
standard molecular biology techniques there are still a
number of caveats that should be kept in mind, including
the post-transcriptional modifications that cannot be
readily detected by gene expression changes and the large
amounts of data variability that limits the careful analysis
of every gene and highlights the necessity for further con-
firmatory tests and studies utilizing human lung samples.
One of the first gene-profiling studies to address an
important disease process, such as sepsis at a multisystem
level, was that of Ward et al. [65] Using DNA microarray
platforms, authors examined the sepsis-induced gene
expression patterns at a multiorgan level, in mice. One of
the most intriguing aspects of this study is the identifica-
tion of genes (many of them not previously associated
with sepsis response) that have a distinctive organ-specific
expression profile as well as of genes with a relatively uni-
versal response to sepsis indicating interesting associa-
tions between organs. Validation of the data was
performed by Northern blot analysis in only four selected
genes and similar quantitative concordance between the
two analyses was achieved. Although the microarray anal-
ysis provides an informative insight in the pathogenetic
mechanisms of a complex disease process the lack of suf-
ficient confirmatory tests applied in all studied genes and
the absence of functional genomics that will help us
understand the exact role of the newly characterized genes
in the septic response pose major limitations in the study
and illuminates the need for further characterization of
the sepsis-induced gene expression profiles.
In summary, these studies exhibit the crucial role of a
novel molecular technology in discovering, through glo-
bal analysis of gene expression, genes previously identi-
fied only by their DNA sequence. Although the array
analysis provides in some studies a comprehensive over-
view of gene expression in the lung during ALI
[56,58,61,64], and sepsis [65] and after hyperoxia [64],
however there are numerous concerns arising from the
large amounts of data variability, the lack of proteomics
approaches in most of them and the controversial find-
ings of microarray analysis and confirmational tech-
niques. Unfortunately only three studies [58,61 and 64]
used independent methodological criteria to validate a
relatively small portion of their results, evidence that
highlight the necessity for further more widespread evalu-
ation of these findings. With the use of these approaches,
more precise diagnosis and risk assessment of ALI based
on expression profiles can be achievable in the next ten
years, leading to more accurate determination of progno-
sis and new therapeutical interventions (Table 5).
5. Microarrays in sarcoidosis
Sarcoidosis is a chronic systemic disorder characterized by
the presence of non-caseating granulomas and accumula-
tion of T-lymphocytes and macrophages in multiple
organs [66]. The mechanisms leading to the persistent
accumulation of inflammatory cells are not fully under-
stood. Apoptosis, a dynamic process involved in the con-
trol of the "tissue load" of immune effecter cells at
inflamed sites, limits inflammatory tissue injury and pro-
motes resolution of inflammation [67]. Whether or not
reduced apoptosis is involved in the pathogenesis of sar-
coidosis is unclear. Rutherford et al. [68] in their attempt
to shed further light on apoptosis signals in the peripheral
blood of sarcoidosis patients with self limited and pro-
gressive disease in comparison with healthy controls used
high-density probe arrays containing 12.626 genes.
Though this study demonstrated significant differences in
the expression of apoptosis-related genes in peripheral
blood of patients with acute onset sarcoidosis compared
to controls, ultimately did not manage to show a definite
profile that was suggestive of survival or apoptosis.
Although authors applied functional genomics a potential
criticism of their approach is that they cannot give any
statement on the activity of the apoptotic pathways. To do
so the data should be combined with the proteomics anal-
ysis [69] of proteins involved in apoptosis. The latter will
contribute to the characterization of protein patterns and
will allow for the assessment of overall changes in the pro-
tein content associated with apoptosis.
Collectively these findings not only reveal the importance
of the microarray platforms in identifying gene expression
patterns that give the scientists the opportunity to eluci-
date the pathophysiological processes of complex dis-
eases, such as sarcoidosis but also illuminate some of their
origin disadvantages.
Future directions, challenges and limitations of microarray 
technology
The last five years has seen the emergence of a novel tech-
nology applied in almost every aspect of respiratoryRespiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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research, a technology that has also great future perspec-
tives and may provide scientists with numerous avenues
of investigation that have clinical implications. Since
nowadays, microarray technology has been successfully
used for the identification of potential target genes for
therapeutic intervention in IPF,[22] mechanistic studies
in animal models of asthma [32,45] and IPF,[23,24] and
helped the investigators to shed further light into the tran-
scriptional programs involved in cytokine signaling
[34,36,42] and apoptosis [35,41,61]. Furthermore, this
technology increased our hopes in the field of diagnosis
and clinical assessment of complex diseases such as
asthma [33] and revealed modern approaches in thera-
peutic interventions in asthma [37,43] as well as COPD
[46]. Finally, it provided scientists with useful informa-
tion in their attempt to gain better understanding in
molecular mechanisms regulating several pathological
processes such as IPF, [22-26] asthma, [33,35-39,42]
COPD, [45-48,50,52] lung fibrosis in acute lung injury
[56,61,64,65] and pulmonary edema [58,63,64]. How-
ever, the feeling of excitement arising from the relative
ease of producing the results of microarray experiments
comes to contrast with the confusion arising from the
objective difficulty of dealing with the results.
Managing and mining the huge amount of data generated
by microarray experiments still remains a major challenge
and limitation for most investigators. Whether gene
expression changes are considered primary vs. reactive for
a given disease is a complicated issue, and one can only
begin to judge that if the methods and approaches used to
generate the data are of sufficient scientific rigidity. The
diversity and scope of the data require the creation of
multidisciplinary teams consisting of physicians, biolo-
gists and bioinformaticians (mathematicians, computa-
tional biologists and database managers) [10]. Thus, we
can conclude, that these diverse experimental schemes
pose diverse computational requirements, such as
advanced data mining, clustering and analysis tools,
including interpreting patterns of gene expression with
self-organizing maps.
Because of the statistical issues raised by microarray tech-
nology, it is necessary for any meaningful interpretation
that the data is replicated using independent methodolog-
ical criteria, preferably with separate samples rather than
the tissue or RNA used to derive the original targets. A
rapid high through-put method for confirmation of
microarray data is quantitative RT-PCR. Alternatively,
Northern blots or ribonuclease protection assays provide
the benefit of direct quantification. So far some studies
have started to adapt these approaches (Figure 4) but
there are still limitations. Because a microarray analysis
may reveal putative changes in the expression of tens or
hundreds of genes, it is practically impossible to validate
all of the data. However, it is incumbent upon
investigators to evaluate a reasonable number of biased in
their selection genes. Thus genomics and gene expression
experiments are sometimes derided as "fishing expedi-
tions". Hence it is necessary that these conventional tech-
niques should be coupled with advanced data mining
tools to help the scientists to face the greatest challenge,
namely the extraction of biological meaning from micro-
array data and the prioritization of candidate genes for
follow up [11]. Another challenge is to gain a holistic view
of the human genome and biology, by applying genomic
microarray in combination with the proteomic microar-
ray to overpass the origin disadvantage of microarray tech-
nology that gives the users the view of inducible genes
only. Sequence and gene expression analysis alone is
insufficient to fully inform the investigator on the cell
state and function. To the best of our knowledge only few
of the studies utilizing microarray platforms in respiratory
research has taken advantage of this approach and in a
limited number of genes [69]. This combination would be
crucial to better understand the functional aspects of dis-
ease and to bridge the long way between genotype and
phenotype due to environment-gene interactions [12,70].
Additionally, it will be critical to develop improved meth-
ods for unbiased amplification of small RNA samples so
that meaningful data can be obtained by applying micro-
arrays on small tissue samples and pure cell populations,
such as are samples obtained by microdissection of tissue
sections [47]. This approach will solve the problem cre-
ated by dramatic differences in cellular composition of
affected and unaffected tissue and by spatial and temporal
heterogeneity of disease that limits the optimal
application of microarrays to the study of diseases [27].
Finally it is noteworthy to be mentioned that microarrays
like other new diagnostic and research tools are highly
cost-intensive. Considering the high costs of microarray
based experiments it is important to say that this disad-
vantage will inevitably limit the speed with which they are
introduced into clinical practice and restrict their applica-
tion in university hospitals and other medical institutes
[71]. Therefore it is crucial that academic centers and
other specialized units should understand that joint ven-
tures with biotechnological and pharmaceutical compa-
nies are critical to overlap all the financial obstacles so
that microarray technology will be likely to reach most
large hospitals with huge potential gain in clinically rele-
vant information for individual patients and their
diseases.
Conclusion
Currently, the use of microarray technology in respiratory
research is limited by the tissue sample, incomplete avail-
able arrays and the analysis of data generated from this
technology. Clinical use of microarrays technology is still
in its infancy and remains exploratory. For these array-Respiratory Research 2004, 5:26 http://respiratory-research.com/content/5/1/26
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based methods to become truly revolutionary, they must
become an integral part of the daily activities of the typical
molecular biology laboratory and biomedical institute.
There is plenty of room for technical improvements, fur-
ther development, and more widespread acceptance and
accessibility. Optimistically thinking we expect that over
the next few years the pattern of development and use of
microarrays will be on a similar trajectory to that seen for
computers and other high-tech electronic devices, which
started out as exotic and expensive tools in the hands of
the few developers and then moved quickly to become
easier to use, more available and less expensive. Alterna-
tively authors believe that so far microarrays have not
added much to our understanding and the possibility to
live up to the great 'hype' that was generated belongs to
the distant future.
Our view is that the application of these approaches will
improve dramatically the effectiveness and reliability of
microarray technology in studies of diseases of complex
organs like the lung, and will have a major impact on our
understanding of molecular pathogenesis for the foresee-
able future. Whether our hopes will be fulfilled or dis-
proved remains to be seen.
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